secwatch.observer — SEC 8-K summary
======================================

Issuer:     PFIZER INC (PFE)
CIK:        0000078003
Form:       8-K
Filed at:   2025-02-04T23:59:59+00:00
Accession:  0000078003-25-000017
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pfizer Q4/FY2024 rev $63.6B (+7% op); adj EPS $3.11; reaffirms 2025 guidance
----------------------------------------------------------------------------

- FY2024 revenues $63.6B (+7% operational); excluding COVID products, up 12% operationally.
- FY2024 reported diluted EPS $1.41; adjusted diluted EPS $3.11. Q4 adjusted EPS $0.63.
- Reaffirms FY2025 guidance: revenue $61-$64B, adjusted diluted EPS $2.80-$3.00.
- On track for ~$4.5B net cost savings by end 2025; $1.5B from Manufacturing Optimization by 2027.
- Positive Phase 3 BREAKWATER for Braftovi in mCRC; sold ~$3B Haleon stake; Boshoff named CSO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/78003/000007800325000017/0000078003-25-000017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/78003/000007800325000017/pfe-20250204.htm
  HTML page:      https://secwatch.observer/filing/0000078003-25-000017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer